Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | CTSS | P25774 | 8/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8627281 | 0.85 | NAALAD2 (0.42) | MEN1GAAKMT2AAKT1CTSK | |
| SCHEMBL1979477 | 0.82 | CTSK (0.45) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL2129742 | 0.82 | TDP1 (0.42) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL1486204 | 0.82 | TDP1 (0.42) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL1979479 | 0.82 | CTSK (0.45) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL2837383 | 0.82 | CTSK (0.45) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL201901 | 0.82 | TDP1 (0.42) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL4909422 | 0.82 | NAALAD2 (0.40) | MEN1GAAKMT2AAKT1CTSK | |
| SCHEMBL2279581 | 0.81 | MEN1 (0.39) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL20854164 | 0.81 | MEN1 (0.39) | MEN1GAAKMT2ACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | MEN1 4814/4885GAA 4531/4885KMT2A 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.